Loading search results…

Scholars @ Weill Cornell Medicine

Help & supportPhase 1 prototype

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research24

Loading search results…

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research24

FiltersClear all

Status

Recruiting10
Active, not recruiting3
Completed11

Study type

Interventional24

Phase

Phase 315
Not applicable5
Phase 23
Phase 41

Investigator

Alpana P. Shukla8
Louis J Aronne7
Ana C. Krieger2
Reem Z. Sharaiha2
Daniel W Skupski1

Show all 9Show fewer

Department

Medicine23
Obstetrics and Gynecology1

Condition

Obesity23
Prostatic Neoplasms52
Leukemia, Myeloid, Acute50
Breast Neoplasms43
Heart Failure34

Show all 50Show fewer

Intervention type

Drug18
Other6
Behavioral3
Biological2
Device2
Combination product1

Sponsor type

Industry20
Other academic2
WCM (investigator-initiated)2

Start date

Has results posted6

Obesity×Clear all

Showing 1–20 of 24 studiesSort:

RecruitingInterventional · Not applicableNCT04101669 ↗
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Evaluating the RESET® System for Glycemic Improvement in Patients With Inadequately Controlled Type 2 Diabetes and Obesity
Reem Z. SharaihaPI
Intervention
Device: RESET Liner · Other: Sham
Dates
Sep 2019 – Dec 2027 (est.)

FiltersClear all

Status

Recruiting10
Active, not recruiting3
Completed11

Study type

Interventional24

Phase

Phase 315
Not applicable5
Phase 23
Phase 41

Investigator

Alpana P. Shukla8
Louis J Aronne7
Ana C. Krieger2
Reem Z. Sharaiha2
Daniel W Skupski1

Show all 9Show fewer

Department

Medicine23
Obstetrics and Gynecology1

Condition

Obesity23
Prostatic Neoplasms52
Leukemia, Myeloid, Acute50
Breast Neoplasms43
Heart Failure34

Show all 50Show fewer

Intervention type

Drug18
Other6
Behavioral3
Biological2
Device2
Combination product1

Sponsor type

Industry20
Other academic2
WCM (investigator-initiated)2

Start date

Has results posted6

Obesity×Clear all

Showing 1–20 of 24 studiesSort:

RecruitingInterventional · Not applicableNCT04101669 ↗
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Evaluating the RESET® System for Glycemic Improvement in Patients With Inadequately Controlled Type 2 Diabetes and Obesity
Reem Z. SharaihaPI
Intervention
Device: RESET Liner · Other: Sham
Dates
Sep 2019 – Dec 2027 (est.)

Erica Phillips1
Sarah Schmitz1
Parag Goyal1
Tashara Marie Leak1

Multiple Myeloma32

Neoplasms32

Colitis, Ulcerative29

Atrial Fibrillation27

Carcinoma, Non-Small-Cell Lung27

Crohn Disease27

Recurrence27

COVID-1926

Myelodysplastic Syndromes26

Parkinson Disease24

Neoplasm Metastasis23

Colorectal Neoplasms19

HIV Infections19

Hematologic Neoplasms19

Cardiovascular Diseases18

Depression18

Non-alcoholic Fatty Liver Disease16

Overweight15

Lung Neoplasms14

Melanoma14

Cognitive Dysfunction13

Idiopathic Pulmonary Fibrosis13

Inflammatory Bowel Diseases13

Alzheimer Disease12

Leukemia12

Leukemia, Lymphocytic, Chronic, B-Cell12

Lymphoma, Non-Hodgkin12

Primary Myelofibrosis12

Coronary Artery Disease11

Hypertension11

Hypertension, Pulmonary11

Lung Diseases, Interstitial11

Myeloproliferative Disorders11

Pulmonary Arterial Hypertension11

Stroke11

Chronic Pain10

Hemophilia A10

Leukemia, Myelomonocytic, Chronic10

Lymphoma, Follicular10

Lymphoma, Large B-Cell, Diffuse10

Urinary Bladder Neoplasms10

Burkitt Lymphoma9

Fibrosis9

Liver Diseases9

Carcinoma, Renal Cell8

Sponsor

GI Dynamics, Inc.

Diabetes type2Obesity

Active, not recruitingInterventional · Phase 3NCT05869903 ↗

A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral Orforglipron Compared With Placebo in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1)

Alpana P. ShuklaPI

Intervention: Drug: Orforglipron · Drug: Placebo
Dates: Jun 2023 – Jul 2025· Results posted
Sponsor: Eli Lilly and Company

ObesityOverweightOverweight or Obesity

RecruitingInterventional · Not applicableNCT06335810 ↗

Reducing Obesity Using Social Ties (ROBUST): Randomized Control Trial

Erica PhillipsPI

Intervention: Behavioral: Social Network Intervention · Behavioral: Individual Lifestyle Intervention · Other: Social Network Member
Dates: Apr 2024 – Dec 2026 (est.)
Sponsor: Weill Medical College of Cornell University

Obesity

Active, not recruitingInterventional · Phase 2NCT06577090 ↗

A Phase 2 Study of QW Nimacimab Injection, Compared to Placebo Injection and QW Weekly Nimacimab Injection Co-administered With Semaglutide in Participants Who Are Overweight or Obese

Louis J AronnePI

Intervention: Biological: Nimacimab injection · Biological: Nimacimab placebo injection · Combination product: semaglutide injection · Biological: Nimacimab 300 mg injection
Dates: Aug 2024 – Nov 2026 (est.)
Sponsor: Skye Bioscience INC

Obesity

RecruitingInterventional · Not applicableNCT06724172 ↗

CHIME: Comparing Health Interventions for Maternal Equity

Daniel W SkupskiPI

Intervention: Behavioral: Self-Management · Behavioral: Community-Based
Dates: Jan 2026 – Jan 2030 (est.)
Sponsor: Stanford University

Obesity and OverweightNutritionChronic Disease+2 more

RecruitingInterventional · Not applicableNCT07090005 ↗

Comparing the Efficacy and Safety of the EndoZipTM System and Apollo Endoscopic Sleeve Gastroplasty (ESG), Followed by Behavioral Modifications, in Obese Patients Who Have Not Achieved Weight Reduction Through Non-surgical Methods.

Reem Z. SharaihaPI

Intervention: Device: EndoZip System · Device: OverStitch Endoscopic Suturing System (ESG)
Dates: Nov 2025 – Jun 2027 (est.)
Sponsor: Nitinotes Surgical Ltd.

ObesityOverweight

RecruitingInterventional · Phase 4NCT07257484 ↗

Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors

Sarah SchmitzPI

Intervention: Drug: Tirzepatide
Dates: Jun 2026 – Dec 2027 (est.)
Sponsor: Weill Medical College of Cornell University

Obesity (Disorder)Breast Cancer

Active, not recruitingInterventional · Phase 3NCT07357415 ↗

A Phase 3b Study to Investigate the Efficacy and Safety of Different Retatrutide Dose Escalation Schemes in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Controlled, Double-Blind Trial

Alpana P. ShuklaPI

Intervention: Drug: Retatrutide
Dates: Jan 2026 – Oct 2028 (est.)
Sponsor: Eli Lilly and Company

ObesityOverweight

RecruitingInterventional · Phase 3NCT07392190 ↗

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Persistent Obesity or Overweight Treated With a Weekly Incretin, With and Without Type 2 Diabetes

Louis J AronnePI

Intervention: Drug: Eloralintide · Drug: Placebo
Dates: Feb 2026 – Jun 2028 (est.)
Sponsor: Eli Lilly and Company

OverweightObesity

RecruitingInterventional · Phase 3NCT07571005 ↗

Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Overweight or Obesity, and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure (AMAZE 3)

Ana C. KriegerPI

Intervention: Drug: NNC0487-0111 · Drug: Placebo (matched to NNC0487-0111)
Dates: May 2026 – Jul 2028 (est.)
Sponsor: Novo Nordisk Pharmaceuticals, Inc.

ObesityOverweightObstructive Sleep Apnoea

RecruitingInterventional · Phase 3NCT07571109 ↗

Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Overweight or Obesity, and Obstructive Sleep Apnoea Treated With Positive Airway Pressure (AMAZE 4)

Ana C. KriegerPI

Intervention: Drug: NNC0487-0111 · Drug: Placebo (matched to NNC0487-0111)
Dates: May 2026 – Jun 2028 (est.)
Sponsor: Novo Nordisk Pharmaceuticals, Inc.

ObesityOverweightObstructive Sleep Apnoea

RecruitingInterventional · Phase 3NCT07595549 ↗

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE-MONTHLY PF-08653944 IN ADULTS WITH OVERWEIGHT OR OBESITY (VESPER-6)

Alpana P. ShuklaPI

Intervention: Drug: PF-08653944 · Other: Placebo
Dates: Jun 2026 – May 2028 (est.)
Sponsor: Pfizer, Inc.

ObesityOverweight and/or ObesityOverweight

RecruitingInterventional · Phase 3NCT07720271 ↗

Efficacy and Safety of Once-daily Oral Zenagamtide in Participants With Obesity (AMAZE 9)

Alpana P. ShuklaPI

Intervention: Drug: zenagamtide · Drug: Placebo
Dates: Aug 2026 – Jun 2028 (est.)
Sponsor: Novo Nordisk Pharmaceuticals, Inc.

OverweightObesity

CompletedInterventional · Phase 3NCT04184622 ↗

Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)

Louis J AronnePI

Intervention: Drug: Tirzepatide · Drug: Placebo
Dates: Dec 2019 – Apr 2022· Results posted
Sponsor: Lilly USA, LLC

OverweightObesity

CompletedInterventional · Phase 3NCT04660643 ↗

Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for Maintenance of Weight Loss in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-4)

Louis J AronnePI

Intervention: Drug: Tirzepatide · Other: Placebo
Dates: Mar 2021 – Apr 2023· Results posted
Sponsor: Eli Lilly and Company

ObesityOverweight

CompletedInterventional · Phase 3NCT04788511 ↗

Effect of Semaglutide 2.4 mg Once Weekly on Function and Symptoms in Subjects With Obesity-related Heart Failure With Preserved Ejection Fraction

Parag GoyalPI

Intervention: Drug: Semaglutide · Drug: Placebo (semaglutide)
Dates: Mar 2021 – Apr 2023· Results posted
Sponsor: Novo Nordisk Pharmaceuticals, Inc.

Obesity

CompletedInterventional · Phase 2NCT05295875 ↗

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled and Parallel Group 48-Week Study to Evaluate the Efficacy and Safety of ALT-801 in the Treatment of Obesity (MOMENTUM Trial)

Louis J AronnePI

Intervention: Drug: ALT-801 · Other: Placebo
Dates: Mar 2022 – Sep 2023
Sponsor: Altimmune, Inc.

Obesity/Overweight

CompletedInterventional · Phase 3NCT05394519 ↗

Efficacy and Safety of Cagrilintide s.c. 2.4 mg in Combination With Semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly in Participants With Overweight or Obesity and Type 2 Diabetes

Alpana P. ShuklaPI

Intervention: Drug: Cagrilintide · Drug: Semaglutide · Drug: Placebo cagrilintide · Drug: Placebo semaglutide
Dates: Feb 2023 – Jan 2025
Sponsor: Novo Nordisk Pharmaceuticals, Inc.

OverweightObesityType 2 Diabetes Mellitus

CompletedInterventional · Not applicableNCT05396443 ↗

A Telehealth Lifestyle Intervention for Black Adolescent Girls at Risk for Type 2 Diabetes: A Pilot Study

Tashara Marie LeakPI

Intervention: Behavioral: Black Girls for Wellness Telehealth
Dates: Aug 2022 – Feb 2025
Sponsor: Weill Medical College of Cornell University

Obesity, ChildhoodType2Diabetes

CompletedInterventional · Phase 2NCT05616013 ↗

A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of Intravenous Bimagrumab, Alone or in Addition to Open Label Subcutaneous Semaglutide, to Investigate the Efficacy and Safety in Overweight or Obese Men and Women

Louis J AronnePI

Intervention: Biological: Bimagrumab · Drug: Semaglutide · Other: Placebo
Dates: Nov 2022 – May 2024· Results posted
Sponsor: Versanis Bio

ObesityObeseOverweight or Obesity

‹ Prev1 2 Next ›